Form 4: Seres Therapeutics Executive David S. Ege Reports Stock Transactions

David S. Ege, Executive Vice President and Chief Technology Officer of Seres Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Summary

• On August 15, 2024, David S. Ege acquired 2,969 shares of common stock through the vesting of restricted stock units.
• On August 16, 2024, Ege sold 1,128 shares of common stock at an average price of $0.84.
• Following these transactions, Ege directly owns 77,575 shares of Seres Therapeutics common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2023, to cover taxes related to the vesting of restricted stock units.
• The restricted stock units vest quarterly, with 25% vesting on February 15, 2024, and the remainder vesting in 12 equal quarterly installments.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions appear to be routine and pre-planned to cover tax obligations related to stock vesting. There is no indication of unusual activity or concern.

Positives

• The transactions are part of a pre-arranged Rule 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate market sentiment.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Executive stock transactions are common in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid accusations of insider trading.
• The vesting schedule of the restricted stock units (25% initially, then quarterly) is a typical arrangement for executive compensation packages.

Stakeholder Impact

• The transactions are unlikely to have a significant impact on stakeholders as they are part of a pre-arranged plan and involve a relatively small number of shares.

Key Dates